The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Lilly
Consulting or Advisory Role - Beta Cat Pharmaceuticals
Research Funding - AB Science (Inst); Daiichi Sankyo (Inst); eleison pharmaceuticals (Inst); Lilly (Inst); Morphotek (Inst); Pfizer (Inst); TRACON Pharma (Inst)
A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results.
 
Steven Attia
Consulting or Advisory Role - EMD Serono; Karyopharm Therapeutics
Research Funding - AB Science (Inst); Bayer (Inst); Bayer (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); Immune Design (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Novartis (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst); ZIOPHARM Oncology (Inst)
 
Vanessa Bolejack
No Relationships to Disclose
 
Kristen N. Ganjoo
Consulting or Advisory Role - Novartis
 
Suzanne George
Stock and Other Ownership Interests - Abbvie (I)
Consulting or Advisory Role - AstraZeneca
Research Funding - Bayer (Inst); Blueprint Genetics (Inst); Deciphera (Inst); Novartis (Inst); Pfizer (Inst)
 
Mark Agulnik
Consulting or Advisory Role - Eisai; Janssen; Lilly; Novartis
Speakers' Bureau - Eisai; Janssen; Novartis
 
Daniel A. Rushing
Honoraria - Bayer; Eisai; Lilly
Consulting or Advisory Role - Bayer; Eisai; Lilly
 
Elizabeth Trice Loggers
Research Funding - Daiichi Sankyo (Inst)
 
Michael B. Livingston
No Relationships to Disclose
 
Jennifer A. Wright
No Relationships to Disclose
 
Sant P. Chawla
Employment - Counterpoint Biomedica; Prana Biotechnology; Uptick Health
Leadership - Counterpoint Biomedica; Prana Biotechnology; Uptick Health
Stock and Other Ownership Interests - Counterpoint Biomedica; Prana Biotechnology; Uptick health
Honoraria - Amgen; CytRx Corporation; Johnson & Johnson; Morphotek; PharmaMar; Threshold Pharmaceuticals; TRACON Pharma
Consulting or Advisory Role - Amgen; CytRx Corporation; Eisai; HERON; Johnson & Johnson; Morphotek; PharmaMar; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - HERON; Janssen
Research Funding - Amgen; Bristol-Myers Squibb; CytRx Corporation; Eisai; Immune Design; Johnson & Johnson; Morphotek; PharmaMar; Threshold Pharmaceuticals; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Counterpoint Biomedica; Prana Biotechnology; uptick health
Expert Testimony - Novartis
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; CytRx Corporation; Eisai; Johnson & Johnson; Morphotek; PharmaMar; Threshold Pharmaceuticals; TRACON Pharma
 
Scott H. Okuno
Consulting or Advisory Role - EMD Serono
 
Denise K. Reinke
Research Funding - Bayer (Inst); Tesaro (Inst); Threshold Pharmaceuticals (Inst)
 
Richard F. Riedel
Employment - Biotech Prosthetic Orthotics of North Carolina (I); Limbguard (I)
Leadership - Biotech Prosthetic Orthotics of North Carolina (I); Limbguard (I)
Stock and Other Ownership Interests - Biotech Prosthetic Orthotics of North Carolina (I); Limbguard (I)
Honoraria - Novartis
Consulting or Advisory Role - CytRx Corporation; Daiichi Sankyo; Eisai; GlaxoSmithKline; Lilly; Merck; Morphotek; Novartis
Research Funding - AADi (Inst); Agios (Inst); Arog (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Immune Design (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Plexxikon (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - PandoNet - Limbguard (I)
Travel, Accommodations, Expenses - Daiichi Sankyo; EMD Serono; Janssen; Novartis
 
Lara Emily Davis
Consulting or Advisory Role - Eisai
Research Funding - Epizyme (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst)
 
Christopher W. Ryan
Consulting or Advisory Role - Eisai; EMD Serono; Exelixis; Novartis
Research Funding - Argos Therapeutics (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline/Novartis (Inst); Janssen (Inst); MabVax (Inst); Merck (Inst); Morphotek (Inst); OSI Pharmaceuticals (Inst); Pfizer (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst)
 
Robert G. Maki
Honoraria - Lilly
Consulting or Advisory Role - AADi; Arcus Ventures; Bayer; Eisai; Gem Pharmaceuticals; Immune Design; Karyopharm Therapeutics; Lilly/ImClone; Presage Biosciences; SARC: Sarcoma Alliance for Research though Collaboration; TRACON Pharma
Research Funding - Immune Design (Inst); Lilly (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Uptodate: I write and edit chapters for their online text book.
Travel, Accommodations, Expenses - Bayer/Onyx; Immune Design; TRACON Pharma